Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

Dublin, April 23, 2018 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs" report has been added to ResearchAndMarkets.com's offering.

The report "Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 Novel JAK and IL6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster AntiTNFs" provides the current AsiaPacific RA market contains novel products, including sirukumab, an antiIL6 human mAb; Peficitinib, Upadacitinib and Filgotinib, which are JAK1 inhibitors; Olokizumab, an antiIL6 humanized IgG4 mAb; and RCT18, a recombinant human Blymphocyte stimulating factor (BLyS) receptor antibody fusion protein.

The RA therapeutic market has become very competitive due to the high number of new drug approvals. Competition is fierce, particularly among TNFa inhibitors, which dominate the treatment market for RA patients who are refractory to traditional disease modifying anti-rheumatic drugs (DMARD).

Despite this, 30% of RA patients fail to attain a clinical response when treated with TNFa inhibitors. However, other targeted programs, as well as newly marketed smallmolecule DMARDs such as the Janus kinase (JAK) inhibitor Xeljanz (tofacitinib), have the potential to replace ineffective TNFa inhibitors. Recently published study results of Xeljanz have shown a significant reduction in the risk of developing cardiac diseases such as heart attack and stroke in patients with RA.

The advent of biologic disease modifying antirheumatic drugs (DMARD) has boosted the rheumatoid arthritis (RA) market tremendously over the last two decades. Growth is expected to continue at a moderate pace from around $5.6 billion in 2016 to more than $9.5 billion in 2023 at a compound annual growth rate (CAGR) of over 8% in the Asia-Pacific (APAC) markets of India, Australia, China, South Korea and Japan. Japan accounted for the majority of the market in 2016 with a 65.4% share, followed by China, Australia, India and South Korea with about 12.7%, 8.6%, 8.1% and 5.2% respectively.

Recently approved therapies anticipated to have a high impact include Eli Lilly and Incyte's baricitinib and Sanofi and Regeneron's sarilumab. Along with recently approved therapies, the entry of new therapies over the forecast period will stimulate market growth. Promising pipeline candidates include Johnson & Johnson (J&J) and GlaxoSmithKline (GSK)'s sirukumab, and Galapagos's filgotinib. Galapagos entered into a global collaboration agreement with Gilead in 2015 to develop and commercialize filgotinib for the treatment of inflammatory indications.

Key Topics Covered:

1 Introduction
1.1 Disease Introduction
1.2 Epidemiology
1.3 Symptoms
1.4 Etiology and Pathophysiology
1.5 Diagnosis
1.5.1 Physical Examination
1.5.2 Blood Tests
1.5.3 1987 Rheumatoid Arthritis Classification
1.5.4 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis
1.6 Prognosis
1.7 Treatment Guidelines and Options
1.7.1 Pharmacological
1.7.2 Methotrexate
1.7.3 Hydroxychloroquine
1.7.4 Leflunomide
1.7.5 Sulfasalazine
1.7.6 Cyclosporine
1.7.7 Xeljanz (tofacitinib)
1.7.8 Other Non-biologics
1.7.9 Biologic Disease-Modifying Anti-rheumatic Drugs
1.7.10 Disease Scoring Methods for Measuring Treatment Efficacy
1.8 Co-morbidities and Complications

2 Marketed Products
2.1 Overview
2.2 Small-Molecule Disease-Modifying Anti-rheumatic Drugs
2.2.1 Methotrexate-Based Products
2.2.2 Xeljanz (tofacitinib) - Pfizer
2.3 Biologic Disease-Modifying Anti-rheumatic Drugs
2.3.1 Remicade (infliximab) - Johnson & Johnson
2.3.2 Humira (adalimumab) - AbbVie
2.3.3 Enbrel (etanercept) - Amgen
2.3.4 Rituxan/MabThera (rituximab) - Biogen Idec and Genentech
2.3.5 Orencia (abatacept) - Bristol-Myers Squibb
2.3.6 Simponi (golimumab) - Johnson & Johnson, Merck
2.3.7 Cimzia (certolizumab pegol) - UCB
2.3.8 Actemra (tocilizumab) - Roche
2.3.9 Olumiant (baricitinib) - Eli Lilly
2.3.10 Kevzara (Sarilumab) - Regeneron/Sanofi
2.3.11 Prolia (denosumab) - Amgen/Daiichi Sankyo
2.4 Comparative Efficacy and Safety of Marketed Products
2.4.1 Conventional Synthetic Disease Modifying Anti-rheumatic Drugs (csDMARDs)
2.4.2 Anti-TNF-a Biologic Disease Modifying Anti-rheumatic Drugs (bDMARDs)
2.4.3 Non-anti-TNF-a Biologic Disease Modifying Anti-rheumatic Drugs
2.4.4 Targeted Synthetic Disease Modifying Anti-rheumatic Drugs

3 Product Pipeline
3.1 Overview
3.2 Pipeline Distribution by Phase of Development, Molecule Type, Route of Administration and Novelty
3.3 Pipeline Distribution by Molecular Target
3.4 Promising Pipeline Candidates
3.4.1 Sirukumab - Johnson & Johnson
3.4.2 Peficitinib - Astellas
3.4.3 Upadacitinib - AbbVie
3.4.4 Filgotinib - Galapagos
3.4.5 Olokizumab - R-Pharm
3.4.6 RCT-18 - Yantai RC-Pharma
3.5 Comparative Efficacy and Safety of Pipeline Products
3.6 Product Competitiveness Framework

4 Clinical Trial Analysis
4.1 Failure Rate
4.1.1 Overall Failure Rate
4.1.2 Failure Rate by Phase and Molecule Type
4.1.3 Failure Rate by Phase and Molecular Target
4.2 Clinical Trial Duration
4.2.1 Clinical Trial Duration by Molecule Type
4.2.2 Clinical Trial Duration by Molecular Target
4.3 Clinical Trial Size
4.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
4.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
4.4 Summary of Clinical Trial Metrics

5 Multi-Scenario Forecast
5.1 Geographical Markets
5.2 APAC Markets
5.3 India
5.4 China
5.5 Australia
5.6 South Korea
5.7 Japan

6 Market Dynamics (Drivers and Barriers) of RA Therapeutics Market
6.1 Drivers
6.1.1 Rising Prevalence in an Aging Population
6.1.2 Launch of Novel Drugs: Oral JAK Inhibitors and Novel Biologics
6.1.3 Increasing Awareness of RA
6.2 Barriers
6.2.1 Increasing Use of Complementary and Alternative Medicine
6.2.2 Launch of Cheaper Biosimilars
6.2.3 Unmet Needs for Efficacious Therapies Diminishing

7 Deals and Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region and Value
7.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
7.1.3 Deal Value by Stage of Development, Molecule Type and Molecular Target
7.1.4 Maruho Enters into Licensing Agreement with 4SC for a Preclinical Compound
7.1.5 CSL Enters into Licensing Agreement with Momenta Pharmaceuticals for M230 Preclinical Product Candidate
7.1.6 Mylan Enters into Licensing Agreement with Momenta Pharmaceuticals for Biosimilar Candidates
7.1.7 Ablynx Enters into a Licensing Deal with AbbVie for the Nanobody ALX-0061
7.2 Co-development
7.2.1 Deals by Region and Value
7.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
7.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
7.2.4 Sanofi Enters into an Agreement with JHL Biotech
7.2.5 Gilead Sciences Enters into Co-development Agreement with Galapagos
7.2.6 Epirus Enters into an Agreement with Orygen Biotecnologia
7.2.7 Dynavax Enters into Co-development Agreement with GlaxoSmithKline

8 Appendix

Companies Mentioned

• AbbVie
• Amgen
• Amgen
• Daiichi Sankyo
• Biogen Idec
  
• Genentech
• Bristol-Myers Squibb
• Eli Lilly
• Johnson & Johnson
• Merck
• Pfizer
• Regeneron
• Sanofi
• Roche
• UCB

For more information about this report visit https://www.researchandmarkets.com/research/64pp28/rheumatoid?w=12

                    
                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             Related Topics: Biosimilars and Biosuperiors, Musculoskeletal Disorders Drugs